| Anti-CD20 monoclonal antibodies: reviewing a revolution JML Casan, J Wong, MJ Northcott, S Opat Human vaccines & immunotherapeutics 14 (12), 2820-2841, 2018 | 102 | 2018 |
| Estimation of central aortic blood pressure: a systematic meta-analysis of available techniques O Narayan, J Casan, M Szarski, AM Dart, IT Meredith, JD Cameron Journal of hypertension 32 (9), 1727-1740, 2014 | 102 | 2014 |
| Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance M Fareh, W Zhao, W Hu, JML Casan, A Kumar, J Symons, JM Zerbato, ... Nature communications 12 (1), 4270, 2021 | 53 | 2021 |
| Radiation dose in 320-slice multidetector cardiac CT: a single center experience of evolving dose minimization MK Tung, JD Cameron, JM Casan, M Crossett, JM Troupis, IT Meredith, ... Journal of Cardiovascular Computed Tomography 7 (3), 157-166, 2013 | 20 | 2013 |
| The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary A ustralian patient cohort P Satasivam, F Reeves, M Lin, J Daruwalla, J Casan, C Lim, PL Royce BJU international 110, 80-84, 2012 | 12 | 2012 |
| Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma S Ratnasingam, J Casan, J Shortt, E Hawkes, M Gilbertson, Z McQuilten, ... Scientific reports 9 (1), 13544, 2019 | 11 | 2019 |
| Role of conventional karyotyping in multiple myeloma in the era of modern treatment and FISH analysis CY Soekojo, G Wang, Y Chen, J Casan, G Wolyncewicz, A Lin, LM Poon, ... Clinical Lymphoma Myeloma and Leukemia 19 (8), e470-e477, 2019 | 8 | 2019 |
| Rivaroxaban in treatment refractory heparin-induced thrombocytopenia JML Casan, G Grigoriadis, N Chan, S Chunilal Case Reports 2016, bcr2016216110, 2016 | 7 | 2016 |
| The effect of treatment delays associated with inpatient inter-hospital transfer from peripheral to tertiary hospitals for the surgical treatment of cardiology patients S Prabhu, D Blusztein, D Jackson, M Sharma, S Arunothayaraj, ... Heart, Lung and Circulation 25 (1), 75-81, 2016 | 7 | 2016 |
| Mechanisms of platelet dysfunction in patients with implantable devices J Casan, RK Andrews, EE Gardiner, AK Davis Seminars in Thrombosis and Hemostasis 44 (01), 012-019, 2018 | 6 | 2018 |
| Degraders upgraded: the rise of PROTACs in hematological malignancies JML Casan, JF Seymour Blood 143 (13), 1218-1230, 2024 | 5 | 2024 |
| Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry BMC Medical Research Methodology 22 (1), 266, 2022 | 5 | 2022 |
| Atraumatic splenic rupture following IVIg for parvovirus B19 pure red cell aplasia post renal transplant M Tiong, J Casan, C McLean Transplant Infectious Disease 21 (2), e13045, 2019 | 4 | 2019 |
| Perturbation of hemostatic function by nonbiologic surfaces HC Kwaan, J Teruya Seminars in thrombosis and hemostasis 44 (01), 005-006, 2018 | 3 | 2018 |
| Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon TE Lew, R Bennett, VS Lin, A Whitechurch, SM Handunnetti, P Marlton, ... Blood Advances 8 (6), 1439-1443, 2024 | 2 | 2024 |
| R‐IVAC salvage therapy in relapsed and refractory DLBCL J Casan, G Wolyncewicz, W Alam, S Opat, G Gregory, J Shortt, S Patil, ... Hematological Oncology 37, 435-436, 2019 | 2 | 2019 |
| Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: Not yet the standard of care JML Casan, A Barraclough, J Shortt, EA Hawkes The Lancet Haematology 6 (3), e119, 2019 | 2 | 2019 |
| Beliefs regarding medications influence patients’ adherence to medical therapy one year following percutaneous coronary intervention MA Austin, JML Casan, MA Baldi, IT Meredith, SA Hope Heart, Lung and Circulation 18, S92, 2009 | 2 | 2009 |
| Molecular principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision C Shembrey, R Yang, J Casan, W Hu, T Sadras, K Prasad, J Shortt, ... bioRxiv, 2023.09. 26.557083, 2023 | 1 | 2023 |
| Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions W Hu, A Kumar, S Qi, T Sadras, JML Casan, D Ma, LM Brown, M Haber, ... bioRxiv, 2022.06. 22.497105, 2022 | 1 | 2022 |
